Physician profile
Phillis Wu
NPI 1174716328
$2,340.52
in general payments reported to CMS, 2019-2025
34 companies · $625 in 2025
The $625 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $101 · 2021: $35.99 · 2022: $134 · 2023: $407 · 2024: $459 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.50 |
| Education | $190.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $317.11 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Janssen Biotech, INC. | $228.35 | 2024-2025 | Imbruvica, Talvey, Tecvayli |
| Seagen INC. | $210.50 | 2019-2023 | Adcetris |
| Alexion Pharmaceuticals, INC. | $136.26 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $130.54 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $104.80 | 2023-2025 | Calquence, Imfinzi, Tagrisso |
| Regeneron Healthcare Solutions, INC. | $95.83 | 2019-2024 | Libtayo |
| Incyte Corporation | $83.17 | 2019-2025 | Zynyz, Monjuvi, Jakafi |
| Merck Sharp & Dohme LLC | $82.57 | 2025 | Keytruda, Welireg |
| E.R. Squibb & Sons, L.L.C. | $82.36 | 2019-2025 | Opdualag |
| Eisai INC. | $81.44 | 2019-2025 | |
| Adc Therapeutics America, INC. | $80.13 | 2023-2025 | |
| Genentech USA, INC. | $59.62 | 2019-2025 | Tecentriq |
| Abbvie INC. | $54.57 | 2024-2025 | |
| Genzyme Corporation | $46.19 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.64 | 2019-2020 | |
| Foundation Medicine, INC. | $42.75 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.60 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $38.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.30 | 2019-2020 | |
| Geron Corporation | $31.38 | 2025 | Rytelo |
| Gilead Sciences, INC. | $30.57 | 2024 | |
| Genmab U.S., INC. | $30.17 | 2025 | Epkinly |
| Dendreon Pharmaceuticals LLC | $29.91 | 2025 | Provenge |
| Amgen INC. | $28.75 | 2020 | |
| Tersera Therapeutics LLC | $28.70 | 2023 | Xermelo |
| Mirati Therapeutics, INC. | $23.61 | 2024 | Krazati |
| Novartis Pharmaceuticals Corporation | $23.59 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $23.19 | 2019 | |
| Daiichi Sankyo INC. | $22.84 | 2025 | Enhertu |
| Puma Biotechnology, INC. | $20.15 | 2019 | |
| Array Biopharma INC | $18.36 | 2025 | Braftovi, Lorbrena, Xalkori |
| Agios Pharmaceuticals, INC. | $18.24 | 2025 | Pyrukynd |
| Sanofi-Aventis U.S. LLC | $16.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillis Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.